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Aneurysmal subarachnoid hemorrhage (SAH) is associated with high morbidity and mortality. 
Devastating post‑SAH complications, such as cerebral vasospasm (CVS), delayed cerebral ischemia 
or seizures to mention a few, are mainly responsible for the poor clinical outcome. Inflammation 
plays an indispensable role during early brain injury (EBI) and delayed brain injury (DBI) phases over 
which these complications arise. T helper cells are the major cytokine secreting cells of adaptive 
immunity that can polarize to multiple functionally unique sub‑populations. Here, we investigate 
different CD4+ T cell subsets during EBI and DBI phases after SAH, and their dynamics during post‑
SAH complications. Peripheral venous blood from 15 SAH patients during EBI and DBI phases, was 
analyzed by multicolour flowcytometry. Different subsets of CD3+ CD4+ T cells were characterized by 
differential cell surface expression of CXCR3 and CCR6 into Th1, Th2, Th17, whereas Tregs were defined 
by  CD25hiCD127lo. The analysis of activation states was done by the expression of stable activation 
markers CD38 and HLA‑DR. Interestingly, compared to healthy controls, Tregs were significantly 
increased during both EBI and DBI phases. Different activation states of Tregs showed differential 
significant increase during EBI and DBI phases compared to controls. HLA‑DR− CD38+ Tregs were 
significantly increased during DBI phase compared to EBI phase in SAH patients developing CVS, 
seizures and infections. However, HLA‑DR− CD38− Tregs were significantly reduced during EBI phase 
in patients with cerebral ischemia (CI) compared to those without CI. HLA‑DR− CD38− Th2 cells were 
significantly increased during EBI phase compared to controls. A significant reduction in Th17/Tregs 
and HLA‑DR− CD38+ Th17/Tregs ratios was observed during both EBI and DBI phases compared to 
controls. While HLA‑DR− CD38− Th17/Tregs and HLA‑DR− CD38− Th1/Th2 ratios were impaired only 
during EBI phase compared to controls. In conclusion, CD4+ T cell subsets display dynamic and unique 
activation patterns after SAH and during the course of the manifestation of post‑SAH complications, 
which may be helpful for the development of precision neurovascular care. However, to claim this, 
confirmatory studies with larger patient cohorts, ideally from different ethnic backgrounds, are 
required. Moreover, our descriptive study may be the grounds for subsequent lab endeavors to explore 
the underlying mechanisms of our observations.
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Aneurysmal subarachnoid hemorrhage (SAH) involves a sentinel subarachnoidal bleed as a consequence of a 
ruptured intracranial aneurysm and confers significant morbidity and mortality among other  strokes1–3. Despite 
the treatment of the bleeding aneurysms by endovascular coiling or neurosurgical clipping, still majority of the 
patients confront life threatening complications including cerebral vasospasm (CVS), delayed cerebral ischemia/
infarction (DCI), seizures, cortical spreading depression (CSD), chronic hydrocephalus, infections and dete-
riorate later  on1,4,5. The brain injury after SAH occurs in two phases; an early brain injury (EBI) occurs due to 
elevated intracranial pressure due to ruptured aneurysms within 72 h of SAH and a delayed brain injury due 
to secondary tissue ischemia over 3–14 days after  SAH6,7. A great body of evidence highlights the critical role 
of sterile inflammation during these brain injury phases, which is marked by the release of “damage associated 
molecular pattern molecules”—DAMPs, cytokines and activation of immune  cells8–13.
Activated lymphocytes are known to facilitate both the clearance of damaged or infected cells and neutraliza-
tion of microbes owing to their ability to secrete different  cytokines14. The involvement of lymphocytes in the 
pathophysiology of SAH is evidenced by the observations of lymphocyte infiltrations in the arteries affected 
by CVS, harvested upon  autopsies15 and in aneurysmal tissue resections obtained during aneurysmal clipping, 
showing several T cells, but rarely B  cells16. An experimental SAH study consolidated this observation show-
ing T cell infiltrates in the subarachnoid space, which were closely associated with the cerebral blood  vessels17. 
Interestingly, after two days of SAH induction, the authors found that the T cells and CD4+ T cells (T helper 
cells) achieved the peak levels and persisted significantly in high levels until day 7 compared to sham non-SAH 
 animals17. Furthermore, the peripheral T cells were significantly elevated on day  317. Further adding to the evi-
dence of misregulated T-cell biology in the microenvironment of SAH manifestation, T cells expressing IL-1β 
were also detected in the CSF of SAH  patients18. Intriguingly, various studies have also evaluated T helper cell 
response in the peripheral circulation after  SAH14,19–22. The suppressor lymphocytes (now known as Treg cells) 
from the peripheral blood of SAH patients were shown to have impaired proliferative  capacity23, and afterwards, 
Chrapusta and colleagues have documented a significant decline in CD4+ T cells in SAH patients treated with 
dexamethasone compared to  controls19. The decreased cellular proliferation was associated with increased adhe-
sion of T cells and T cell co-stimulatory properties in the peripheral blood of SAH  patients23. Interestingly, a more 
aggressive T cell adhesion and co-stimulation profile along with increased CD4+ T cells was evident particularly 
in SAH patients presenting with  CVS19. These observations highlight an indispensable role of CD4+ T cells in 
the post-SAH pathology.
Over the recent years, various subsets of CD4+ T cells have been characterized such as Th1, Th2, Th17 and 
Treg cells. Th1 cells secrete interferon (IFN)-γ, express T-bet signature transcription factor and induce cell medi-
ated immune responses against intracellular  pathogens14,19–22. Th2 cells secrete IL-4, IL-5 and IL-13 as major 
cytokines, express GATA3 and mediate antiparasitic immunity and allergic  responses24. Th17 cells secrete an 
important pro-inflammatory cytokine IL-17, express RORγt and provide protection against bacterial and fungal 
infections through the recruitment of neutrophils; and are also implicated in autoimmune  diseases25,26. Treg 
cells express FOXP3 and release cytokines such as IL-10, TGF-β, and IL-3527. These cells play a critical role in 
immune tolerance and prevention against autoimmune diseases by inhibiting the activity of all immune  cells27.
Interestingly, SAH has been shown to lead to  lymphopenia20,21, however, T helper cells expressing transient 
activation marker CD69 have been shown to increase after  SAH20. Contrarily, an early significant decrease in 
T helper cells has been documented in SAH patients with acute focal neurological deficits and may explain 
the immunosuppression after  SAH21. Recently, a study found decrease in T helper cells and Treg cells in SAH 
patients undergoing neurosurgical microclip obliteration of their aneurysms and developing  fever14. Overall, 
however, a very limited number of studies have been done so far aiming to investigate the response of various 
subsets of CD4+ T cells after SAH. For instance, in an experimental endovascular puncture model of SAH, statins 
administration was found to polarize Th1 cells into Th2  cells28. Further, a clinical study comprising both ruptured 
and unruptured intracranial aneurysms has shown a significant increase in Th17 cells and decrease in Th2 cells 
compared to  controls22. However, studies aiming to investigate the dynamics of different CD4+ T cell subsets 
and their activation states after SAH in detail have not been performed so far. Therefore, the current study aims 
to fill this gap of knowledge by characterizing the detailed dynamics of CD4+ T cell subtypes during early and 
delayed brain injury phases after SAH- and during post-SAH complications.
Methods
Ethics statement. This study was performed according to the guidelines of the Helsinki declaration and 
was approved by the local ethics committee of the medical faculty of the University of Bonn, Germany (Refer-
ence Number: LfD 138/2011). Informed consent was obtained from all subjects (SAH patients and healthy con-
trols) or from patients’ legal guardians for unconscious SAH patients by the treating neurosurgeon.
Patient population. We included 15 SAH patients prospectively and 10 healthy controls in this study. 
Peripheral blood was planned between days 1 and 3 (denoting Early Brain Injury (EBI) phase) and between days 
7 and 9 (denoting Delayed Brain Injury (DBI) phase). Blood from healthy patients was taken at one time point. 
Indeed, except a few patients, first sample was collected within 24 h of hospital admission and second sample 
was collected on day 7 in the majority of SAH patients. The exclusion and inclusion criteria, patient monitor-
ing and treatment, and description of different complications have been described  elsewhere8,10,12. The detailed 
characters of patient population and controls are represented in Table 1.
Different subsets of  CD4+ T cells and Tregs were investigated by the approach described by Maecker, et al.29.
Collection of the blood sample and preparation for staining. The peripheral blood of the SAH 
patients and controls was retrieved in EDTA blood tubes (S-Monovette® Sarstedt, Germany). Erythrocyte lysis 
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was achieved with erythrocyte lysis buffer (eBioscience, Germany) at room temperature. Afterwards, centrifu-
gation of the cells was carried out at 350×g for 5  min at 4  °C. A volume of 2  mL of an ice cold FACS flow 
cytometry buffer (BD Biosciences, Germany) was used to wash the cells after discarding the supernatant. Cells 
were resuspended in 1 mL of FACS buffer after washing and then, were counted using countess cell counting 
slides (Catalog # C10283, Eugene, Oregon, USA) by using Countess™ automated cell counter (ThermoFischer 
scientific, Germany). The final concentration of cells was adjusted to one million cells per 100 µL with the FACS 
buffer. Next, flow cytometry tubes (5 mL; Catalog # 55.1578, Sarstedt, Germany) were labelled for stained cells 
and fluorescence minus one (FMO) controls and 100 µL aliquots of the cells were dispensed into the respective 
tubes. A drop of Ultracomp eBeads (eBioscience, Germany) was dispensed into each tube containing 100 µL of 
FCS buffer for the acquisition of the single stained compensation controls. Next, Human Fc block pure (Catalog 
# 564220, BD Biosciences, Germany) was added to the cells and the cells were further incubated for 10 min on 
 ice30.
Staining of blood cells. The cells were then stained with a panel of anti-human antibodies  conjugated 
with different fluorophores against various T cell markers and consisted of CD45 APC-H7, CD3 PE-Cy7, CD4 
BV605, CXCR3 APC, CCR6 BUV737, CD25 PerCP-Cy5.5, CD127 FITC, HLA-DR BV421 and CD38 PE (BD 
Biosciences, USA). Supplementary Table S1 represents the respective clones and catalog details of these antibod-
ies. A sequential staining of cells was performed for chemokine receptors (CXCR3, CCR6) at room temperature 
giving an interval of at least 5 min before addition of the next antibody as proposed by Jalbert et al.31. Next, the 
cells in the stained sample and the FMO control tubes were stained with a master mix of antibodies prepared in 
Brilliant Violet Staining buffer (BV Buffer, BD Biosciences, Germany) for twenty minutes on ice. Later on, 2 mL 
Table 1.  Characters of healthy controls and SAH patients.
Controls (n) 10
Age (years) (mean ± SD) 34.62 (± 13.24)
Females (n) 06
SAH (n) 15
Age (years) (mean ± SD) 52.88 (± 11.81)
Females (n) 06
Treatment modality
 Neurosurgical clipping (n) 06
 Endovascular coiling (n) 09
Intraventricular hemorrhage: IVH (n) 04
Intracerebral bleeding: ICB (n) 06
Both ICB and IVH (n) 04
Hunt and Hess grade (median) 4
 Good grade I–III (n) 06
 Poor grade IV–V (n) 09






Cerebral ischemia (n) 10
Seizures (n) 09
VP-shunt dependent hydrocephalus (n) 05
Infections (n) 08
Delayed Ischemic Neurological Defi-
cits: DINDs (n) 03
Aneurysm location
 Anterior circulation (n) 13
 Posterior circulation (n) 02
GOS (median) 3
 Poor outcome 1–3 (n) 09
 Good outcome 4–5 (n) 06
mRS (median) 4
 Good outcome 0–2 (n) 06
 Poor outcome 3–6 (n) 09
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of the FACS buffer was added to wash the cells and subsequently the cells were resuspended in approximately 
500 µL of the FACS buffer. Hoechst 33258 dye (Sigma Aldrich, Germany), a water soluble fluorescent dye, was 
added (0.1 µg/10 µL) approximately one minute before acquisition of each tube to discriminate between live and 
dead  cells30.
Acquisition and analysis of  CD4+ T cell subsets. The cells were then analyzed on LSR Fortessa™ cell 
analyzer (BD Biosciences, CA, USA) at the Flow Cytometry Core Facility at the Institute of Experimental Immu-
nology, University of Bonn. The flow cytometer settings were validated using 8 peaks SPHERO™ Calibration Par-
ticles as an internal reference (Catalog # 559123, BD Biosciences, CA, USA) and instrument performance was 
monitored every day by running CS&T beads (Catalog # 655050, BD Biosciences, CA, USA) according to the 
vendors recommendations. For both panels, around 350–400 thousand CD45+ leucocyte events were acquired 
for stained cells and 100 thousand CD45+ events for FMO controls. About 10,000 all events were acquired for 
single stained compensation controls. Compensation controls were stained and measured freshly, on each day 
the analysis was performed. The gating strategy is given in Fig. S2. BD FACSDiva™ v6.2 for windows 7 (BD Bio-
sciences, USA) software was used during acquisition on LSR Fortessa, while the data was analyzed afterwards 
using  FlowJoTM Software version 10.2 for Microsoft Windows 7 (Treestar, Ashland, OR)30.
Statistical analysis. The normality of the data was assessed by Shapiro–Wilk test or Kolmogrov–Smirnov 
test. Normally distributed data was expressed as mean ± SEM, whereas non-normally distributed data was dis-
played using box plots with whiskers representing median, interquartile range and minimum and maximum 
values. One way analysis of variance (ANOVA) followed by Tukey’s/Bonferroni’s multiple comparisons post hoc 
test was used for comparison between controls and SAH patients during both EBI and DBI phases for normally 
distributed data. For non-normally distributed data, Krukal–Wallis test was used followed by Dunn’s multiple 
comparisons post hoc test. A p value less than 0.05 was considered as a significant difference between the groups 
being compared. The data was analyzed by using GraphPad Prism 5.00 for windows (CA, USA).
Results
CD4+ T cells response after SAH. Lymphocytes in the peripheral blood of SAH patients and healthy con-
trols were identified by their low SSC and high CD45 expression and were expressed as percentage of CD45+ cells 
to reflect changes compared to all the leukocytes. A lymphopenic response was observed in SAH patients dur-
ing both EBI and DBI phases compared to healthy controls (Fig. 1A). Taking into account this lymphopenic 
response, CD4+ T cells were also significantly reduced during EBI phase among all the leukocytes, i.e., when 
expressed as percentage of CD45+ leukocytes (Fig. 1B). However, no significant difference was observed during 
Figure 1.  Comparison of peripheral blood: (A) lymphocytes (low SSC and high CD45 expressing cells) 
after SAH during EBI and DBI phases with healthy controls; (B) CD4+ T cells (expressed as %age of 
CD45 + leukocytes) after SAH during EBI and DBI phases with healthy controls; (C) CD4+ T cells (expressed as 
%age of lymphocytes) after SAH during EBI and DBI phases with healthy controls; (D) Tregs  (CD25hi  CD127lo, 
expressed as %age of CD3+ CD4+ T cells) after SAH during EBI and DBI phases with healthy controls; (E) 
HLA-DR− CD38− Th2 cells (expressed as %age of CD3+ CD4+ T cells) after SAH during EBI and DBI phases 
with healthy controls; (F) HLA-DR− CD38+ Tregs (expressed as %age of CD3+ CD4+ T cells) after SAH during 
EBI and DBI phases with healthy controls; (G) HLA-DR+ CD38+ Tregs (expressed as %age of CD3+ CD4+ T 
cells) after SAH compared to healthy controls during EBI and DBI phases, (H) HLA-DR− CD38− Tregs 
(expressed as %age of CD3+ CD4+ T cells) after SAH during EBI and DBI phases compared to healthy controls. 
One way ANOVA followed by Tukey’s multiple comparisons test for normally distributed data. Kruskal Wallis 
test followed by Dunn’s multiple comparisons test for non-normally distributed data; A p value < 0.05 was 
considered as a significant difference. *Indicates a p value < 0.05, **indicates a p value < 0.01, ***indicates a p 
value < 0.001. HC healthy controls (n = 10), EBI early brain injury phase after SAH covering days 1–3 (n = 15), 
DBI delayed brain injury phase after SAH covering days 7–9 (n = 15).
5
Vol.:(0123456789)
Scientific Reports |        (2021) 11:14226  | https://doi.org/10.1038/s41598-021-92873-x
www.nature.com/scientificreports/
DBI phase (Fig. 1B). Interestingly, CD4+ T cells were significantly increased among the lymphocyte population 
during both EBI and DBI phases compared to the controls (Fig. 1C).
Regulatory T cells (Tregs) were elevated after SAH. T helper cells have been categorized based upon 
the expression of signature transcription factors and cytokine profiles into various subtypes such as Th1, Th2, 
Th17 and Treg  cells24,25,27. After assessing CD4+ T cells response, we investigated the frequency of Tregs  (CD25hi 
 CD127lo) and different subsets of CD4+ T cells (Th1, Th2 and Th17) based on differential cell surface expression 
of chemokine receptors CXCR3 and CCR6 as described by Maecker, et al.29. Apparently, the levels of Th1 cells 
(CXCR3+ CCR6−) and Th17 cells (CXCR3− CCR6+) appear to be low during EBI phase, however, there was no 
statistically significant difference compared to controls during both EBI and DBI phases (Fig. S1A,B). Likewise, 
there was also no significant difference in Th2 cells (CXCR3− CCR6−) during both EBI and DBI phases com-
pared to healthy controls (Fig. S1C). Intriguingly, Treg cells  (CD25hi  CD127lo), which are immunosuppressive 
cells, were significantly increased during both EBI and DBI phases compared to controls (Fig. 1D).
Assessment of activation states of CD4+ T cell subsets and Tregs. Activation markers can provide 
insights into a disease progress and activity, and therefore, could have a biomarker  potential29. In opposition 
to CD69, which is transiently expressed, CD38 and HLA-DR represent permanent activation  markers29. We 
next investigated the activation markers HLA-DR and CD38 on these different CD4+ T cell subsets. A signifi-
cant increase in Th2 cells lacking both of these activation markers (HLA-DR− CD38−) was observed during 
EBI compared to healthy controls, however, during DBI phase the levels of these cells declined, leaving no sig-
nificant difference compared to controls (Fig.  1E). HLA-DR− CD38+ Tregs were significantly increased dur-
ing DBI phase compared to controls as well as EBI phase (Fig. 1F). Tregs expressing both activation markers 
(CD38+ HLA-DR+) were significantly increased during DBI phase compared to controls (Fig. 1G). However, 
Tregs lacking both of these activation markers (HLA-DR− CD38−) were significantly increased during both EBI 
and DBI phases compared to controls like their parent population (Fig. 1H).
T helper cells, their activation states and post‑SAH complications. SAH patients confront with 
various deteriorating complications during EBI and DBI phases leading to poor clinical  outcomes1,2,4,5. We next 
investigated the response of T helper cell subsets and their activation states in various post-SAH complica-
tions such as CVS, seizures, chronic hydrocephalus, cerebral ischemia (CI) and infections. One of the most 
feared and frequent complication of SAH is  CVS1. There was no significant difference in Tregs in SAH patients 
developing CVS and those developing no CVS during EBI and DBI phases (Fig.  2A). However, Tregs were 
significantly increased in SAH patients with CVS during DBI phase compared to the SAH patients without 
CVS during EBI phase (Fig. 2A). Similar to their parent population, HLA-DR− CD38+ Tregs were significantly 
increased in SAH patients with CVS during DBI phase compared to SAH patients without CVS during EBI 
phase (Fig. 2B). Interestingly, HLA-DR− CD38+ Tregs were significantly increased in SAH patients with CVS 
during DBI phase compared to EBI phase (Fig. 2B). SAH patients who developed seizures also did not show 
any significant difference compared to those without seizures (Fig. 2C). However, HLA-DR− CD38+ Tregs were 
significantly increased in SAH patients developing seizures during DBI phase compared to EBI phase (Fig. 2C). 
Several SAH patients develop ventriculoperitoneal shunt dependent chronic hydrocephalus after SAH. In our 
study group, SAH patients developing chronic hydrocephalus did not show any significant difference in HLA-
DR− CD38+ Tregs compared to those developing no chronic hydrocephalus during both EBI and DBI phases 
(Fig. 2D). However, SAH patients who did not develop chronic hydrocephalus have significantly increased levels 
of HLA-DR− CD38+ Tregs during DBI phase compared to EBI phase (Fig. 2D). Further, SAH patients who did 
not develop chronic hydrocephalus have significantly increased levels of HLA-DR− CD38+ during DBI phase 
compared to SAH patients who developed chronic hydrocephalus during EBI phase (Fig. 2D). SAH patients 
who developed cerebral ischemia/infarction (CI) showed a significant decrease in Tregs during EBI phase com-
pared to SAH patients who did not develop CI during DBI phase (data not shown). Interestingly, SAH patients 
who developed CI showed a significant reduction in Tregs lacking both activation markers (HLA-DR− CD38−) 
compared to those who did not develop CI during EBI phase (Fig. 2E). However, no significant difference was 
observed during DBI phase in HLA-DR− CD38− Tregs in SAH patients with CI compared to SAH patients 
without CI (Fig. 2E). Another factor that contributes to the poor clinical outcome is the frequent development 
of infections in SAH  patients32. SAH patients who developed infections did not show any significant difference 
in Th1 (CXCR3+ CCR6−) and HLA-DR− CD38− Th1 cells compared to SAH patients without infections dur-
ing both EBI and DBI phases (Fig. 2F,G). However, both Th1 cells and HLA-DR− CD38− Th1 cells displayed 
significant increase in SAH patients with infections during the DBI phase compared to SAH patients without 
infections during EBI phase (Fig. 2F,G). Further during DBI phase, HLA-DR− CD38+ Tregs were significantly 
elevated in SAH patients contracting different infections compared to SAH patients without infections during 
EBI phase (Fig. 2H). Some SAH patients also present with extravasation of the blood into the cerebral  ventricles1. 
SAH patients presenting with IVH did not show any significant difference compared to SAH patients without 
IVH in HLA-DR− CD38+ Tregs (Fig. 2I) during both EBI and DBI phases. But, surprisingly this population of 
Tregs (HLA-DR− CD38+) showed significant increase during DBI phase compared to EBI phase in only SAH 
patients without IVH (Fig. 2I).
Imbalance of Th1/Th2, Th17/Tregs and their activation states after SAH. Several studies describe 
the imbalance of T helper cells by assessing the ratio of Th1/Th2 and Th17/Tregs to delineate the pathological 
changes. We have also assessed the Th1/Th2 and Th17/Tregs ratios in SAH patients and controls. There was 
no significant difference in Th1/Th2 ratio among controls and SAH patients (data not shown). Intriguingly, 
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Figure 2.  Comparison of peripheral blood: (A) Tregs  (CD25hi  CD127lo, expressed as %age of CD3+ CD4+ T 
cells) after SAH in patients with cerebral vasospasm (CVS) and without CVS during EBI and DBI phases; (B) 
HLA-DR− CD38+ Tregs (expressed as %age of CD3+ CD4+ T cells) after SAH in patients with CVS and with no 
CVS during EBI and DBI phases; (C) HLA-DR− CD38+ Tregs (expressed as %age of CD3+ CD4+ T cells) after 
SAH in patients with seizures and with no seizures during EBI and DBI phases; (D) HLA-DR− CD38+ Tregs 
(expressed as %age of CD3+ CD4+ T cells) after SAH in patients with shunt dependent chronic hydrocephalus 
and with no shunt dependent chronic hydrocephalus during EBI and DBI phases; (E) HLA-DR− CD38− Tregs 
(expressed as %age of CD3+ CD4+ T cells) after SAH in patients with cerebral ischemia/infarction (CI) and 
with no CI during EBI and DBI phases; (F) Th1 cells (CXCR3+ CCR6− , expressed as %age of CD3+ CD4+ T 
cells) after SAH in patients with infections and without infections during EBI and DBI phases; (G) 
HLA-DR− CD38− Th1 cells (expressed as %age of CD3+ CD4+ T cells) after SAH in patients with infections 
and without infections during EBI and DBI phases; (H) HLA-DR− CD38+ Tregs (expressed as %age of 
CD3+ CD4+ T cells) after SAH in patients with infections and without infections during EBI and DBI phases; (I) 
HLA-DR− CD38+ Tregs (expressed as %age of CD3+ CD4+ T cells) after SAH in patients with IVH and without 
IVH during EBI and DBI phases. One way ANOVA followed by Tukey’s/Bonferroni’s multiple comparisons 
test for normally distributed data. Kruskal Wallis test followed by Dunn’s multiple comparisons test for non-
normally distributed data; A p value < 0.05 was considered as a significant difference. *Indicates a p value < 0.05, 
**indicates a p value < 0.01, ***indicates a p value < 0.001. EBI early brain injury phase after SAH covering days 
1–3 (n = 15), DBI delayed brain injury phase after SAH covering days 7–9 (n = 15).
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Th17/Tregs ratio was significantly lower in SAH patients during both EBI and DBI phases compared to con-
trols (Fig. 3A). HLA-DR− CD38+ Th17/Tregs ratio was also significantly lower during EBI and DBI phases in 
SAH patients compared to controls (Fig. 3B). SAH patients also displayed significantly lower ratios of HLA-
DR− CD38− Th17/Tregs and HLA-DR− CD38− Th1/Th2 during EBI phase compared to controls (Fig. 3C,D). 
Similar analysis in SAH patients developing different complications revealed significant changes only in SAH 
patients contracting different infections. SAH patients contracting different infections displayed higher Th1/Th2 
and HLA-DR− CD38− Th1/Th2 ratios during DBI phase compared to SAH patients without infections during 
EBI phase (Fig. 3E,F).
Correlations of different T helper cell subsets and their activation states with different 
post‑SAH complications. Different subsets of T helper cells showed some significant correlations during 
EBI and DBI phases with various post-SAH complications as shown in Table 2. Interestingly, Tregs were posi-
tively correlated with the development of CVS and negatively correlated with CI development in SAH patients 
during EBI phase. HLA-DR− CD38− Tregs were also negatively correlated with CI development in SAH patients 
during both EBI and DBI phases. However, HLA-DR+ CD38+ Tregs were positively correlated with the contrac-
tion of infections during DBI phase. HLA-DR− CD38+ Tregs were negatively correlated with the development of 
delayed ischemic neurological deficits (DINDs) during DBI phase. HLA-DR+ CD38+ Th1 cells were positively 
correlated with the development of seizures during EBI phase and HLA-DR+ CD38− Th1 cells were negatively 
correlated with ICB in SAH patients during DBI phase. HLA-DR− CD38+ Th2 cells were positively correlated 
with CI development during DBI phase.
Figure 3.  Comparison of peripheral blood: (A) Th17/Tregs ratio after SAH during EBI and DBI phases with 
healthy controls; (B) HLA-DR− CD38+ Th17/Tregs ratio after SAH during EBI and DBI phases with healthy 
controls; (C) HLA-DR− CD38− Th17/Tregs ratio after SAH during EBI and DBI phases with healthy controls; 
(D) HLA-DR− CD38− Th1/Th2 cells ratio after SAH during EBI and DBI phases with healthy controls; (E) Th1/
Th2 cells ratio after SAH in patients with infections and without infections during EBI and DBI phases; (F) 
HLA-DR− CD38− Th1/Th2 cells ratio (expressed as %age of CD3+ CD4+ T cells) after SAH in patients with 
infections and without infections during EBI and DBI phases. One way ANOVA followed by Tukey’s multiple 
comparisons test for normally distributed data. Kruskal Wallis test followed by Dunn’s multiple comparisons 
test for non-normally distributed data; A p value < 0.05 was considered as a significant difference. *Indicates a 
p value < 0.05, **indicates a p value < 0.01, ***indicates a p value < 0.001. HC healthy controls (n = 10), EBI early 
brain injury phase after SAH covering days 1–3 (n = 15), DBI delayed brain injury phase after SAH covering 
days 7–9 (n = 15).
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Discussion
Rapid implementable, minimal invasive diagnostics, that more dynamically and sensitively monitor neurovascu-
lar disease progression are highly needed. We utilized peripheral blood immune cell quantification and charac-
terization to propose a concept to serve this purpose. Our work complements the closure of lack of knowledge, 
as very limited number of studies have investigated the major T helper cell subsets after this potentially lethal 
disease—SAH19–21. In our explorative observational clinical study, we have characterized different CD4+ T cell 
subsets based on differential expression of cell surface receptors along with stable activation markers during EBI 
and DBI phases after SAH.
Immunosuppression is observed after  SAH32. Several lines of evidence indicate a lymphopenic response after 
 SAH20,21. In line with these findings, we found a significant decrease in lymphocytes and CD4+ T cells (expressed 
as frequencies of CD45+ leukocytes to reflect their changes among all other leukocytes) after SAH compared to 
controls (Fig. 1A,B). However, CD4+ T cells among lymphocyte population were increased during both EBI and 
DBI phases after SAH as compared to controls (Fig. 1C), which is in par with findings from Moraes et al.20. Strik-
ingly, among the T helper cell subtypes, Tregs and various activated states of Tregs were significantly increased 
during both EBI and DBI phases after SAH (Fig. 1D,F–H). The robust increase in Tregs after SAH in our study is 
in accordance with that observed after intracerebral  hemorrhage33. HLA-DR− CD38− Th2 cells showed significant 
increase during EBI phase only compared to controls (Fig. 1E). The clinical outcome of SAH patients is worsened 
by complications that develop over two weeks after the sentinel bleed, even though the ruptured aneurysms 
are successfully  secured34. Therefore, we have analyzed the dynamics of CD4+ T cell subsets during different 
post-SAH complications. Interestingly, various activated states of Tregs showed differential expression during 
both EBI and DBI phases in SAH patients with CVS, seizures, infections and shunt-dependent chronic hydro-
cephalus (Fig. 2). Approximately, one third of SAH patients suffer from  seizures5 and two thirds develop cerebral 
vasospasm, which is the most feared and frequent complication after  SAH1. Consequently, the dysregulation of 
HLA-DR− CD38+ Tregs may be a promising biomarker in context to these post-SAH complications. Interest-
ingly, we found an impairment in the balance of Th17/Tregs during EBI and DBI phases after SAH compared to 
controls (Fig. 3A), which is in line with a recent study involving severe grade SAH  patients35. Likewise, various 
activation states of Th17/Tregs showed similar impairment during EBI and DBI phases after SAH compared to 
controls (Fig. 3B,C). Th1/Th2 cells balance and their respective activation states also showed impairment dur-
ing EBI phase after SAH and in SAH patients with infections during DBI phase (Fig. 3D–F). Our data calls for 
confirmation studies to validate the Th17/Treg impairment during SAH complications.
Another peculiar aspect of our study of helper T cell subsets was the analysis of fresh samples immediately 
after collection from the patients and the inclusion of permanent cell surface activation markers such as CD38 
and HLA-DR as opposed to transient activation marker  CD6929. These activation markers of T cells may serve 
as the biomarkers of disease activity and severity and may provide important insights into the disease prognosis 
or underlying immunological dysregulation contributing to the  disease29. Analysis of these activation states 
of T helper cells showed that both CD38 and HLA-DR are differentially expressed on these different subtypes 
of T helper cells (Figs. 1, 2, 3). T cells that show the expression of CD38 have been found to be large in size, 
contain more granules, show reduced proliferation and increased cytokine  secretion36. T cells expressing both 
HLA-DR and CD38 signify the activated states and indicate the advancement of the disease process in case of 
various inflammatory  diseases37. The population of Treg cells that express HLA-DR represent terminally acti-
vated effector Treg cells, which have acquired the ability to profoundly inhibit the proliferation of conventional 
T cells and readily produce cytokines in comparison to Tregs lacking HLA-DR  expression27. The current study 
shows various novel findings with respect to the expression of these activation markers, which need validation 
in larger observational studies.
Despite all of the above-described interesting findings, our study has several fundamental limitations, which 
need to be acknowledged when critically assessing our stated hypothesis. The major limitation is the compara-
tively small sample size. The authors acknowledge that the overall relatively rare clinical occurrence of the disease 
contributes to this fact, however, confirmatory study that includes patients from different backgrounds, with 
sampling performed in multiple different treatment centers is warranted. Although our quality control measures 
aim to standardize the procedures as much as  possible38, however, we cannot exclude that logistics from patient 
Table 2.  Correlations of different T helper cell subsets and their activation states with different post-SAH 
complications.
Sr. # T cell subsets Post-SAH injury phase
Post-SAH characters and 
complications Spearman Rank correlation p value
1 Tregs EBI CVS 0.535 0.040
2 Tregs EBI CI  − 0.524 0.045
3 Tregs HLA-DR− CD38+ DBI DINDs  − 0.541 0.037
4 Tregs HLA-DR− CD38− EBI CI  − 0.556 0.031
5 Tregs HLA-DR− CD38− DBI CI  − 0.556 0.031
6 Tregs HLA-DR+ CD38+ DBI Infections 0.526 0.044
7 Th1 HLA-DR+ CD38+ EBI Seizures 0.520 0.047
8 Th1 HLA-DR+ CD38− DBI ICB  − 0.521 0.047
9 Th2 HLA-DR− CD38+ DBI CI 0.524 0.045
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bedside to the laboratory (transport time, chilling conditions during transport etc.) as well as time to staining and 
FACS data acquisition varied and that is known to risk the introduction of variances on the parameters analyzed. 
Another limitation of our study is that the absolute numbers of the analyzed immune cell populations were not 
assessed. Further, our study lacks the information on naïve, effector, effector memory and central memory dis-
crimination of T helper cells along with the assessment of other lymphocyte populations. Moreover, sex and age 
matching of our study population with control cohort was not possible due to the low number of total patients 
enrolled in the trial. However, our study advocates the involvement and unveils the complexity of CD4+ T cells 
response during early and delayed brain injury after SAH and during post-SAH complications. Technically, 
this study also provides novel insights into high dimensional flow cytometry data in association with clinical 
parameters of SAH patients as an example of forward-thinking, reverse translational neurosurgical research to 
instruct subsequent experimental trials for mechanistic exploitation are also warranted.
Conclusion
CD4+ T cell subsets display dynamic changes during EBI and DBI phases after SAH. CD4+ T cell subsets and 
their activation states were differentially expressed in specific post-SAH complications. Th17/Tregs ratio and 
ratios of their activated states were impaired during EBI and DBI phases after SAH. Our data indicates the 
great potential of peripheral T helper cell-based quantification and characterization for monitoring the disease 
progression after SAH by minimal invasive means. Given the lack of adequate alternatives to effectively do so, 
and the ability to monitor rapid changes using flow cytometry, we believe our results pave the scientific grounds 
justifying the larger follow-up studies dedicated to this issue.
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